Terms: = Colorectal cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG
414 results:
1. pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization.
Yu Y; Nie G; Ren YW; Ouyang L; Ni CM
Cell Cycle; 2024 Mar; 23(6):682-692. PubMed ID: 38794797
[TBL] [Abstract] [Full Text] [Related]
2. Integrating single-cell and spatial analysis reveals muc1-mediated cellular crosstalk in mucinous colorectal adenocarcinoma.
Zhou H; Shen Y; Zheng G; Zhang B; Wang A; Zhang J; Hu H; Lin J; Liu S; Luan X; Zhang W
Clin Transl Med; 2024 May; 14(5):e1701. PubMed ID: 38778448
[TBL] [Abstract] [Full Text] [Related]
3. Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer.
Kawano T; Englisch C; Hisada Y; Paul D; Archibald S; Grover S; Pabinger I; Ay C; Mackman N
Thromb Res; 2024 May; 237():23-30. PubMed ID: 38547690
[TBL] [Abstract] [Full Text] [Related]
4. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M
J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714
[TBL] [Abstract] [Full Text] [Related]
5. [A Case of Stage Ⅳc dMMR Transverse Colon cancer with Complete Response to Combination Therapy with Immune Checkpoint Inhibitor in Stage ⅣB Lung Adenocarcinoma].
Kageyama C; Yoshimatsu K; Tanaka H; Higashida M; Ito Y; Okada T; Endo S; Fujiwara Y; Ueno T
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1114-1116. PubMed ID: 38035848
[TBL] [Abstract] [Full Text] [Related]
6. Impacts of some clinicopathodemography and colorectal tissues key cell cycle and mucin stabilizing molecules on the metastasis trend in colorectal cancer patients.
Ghorbani Ranjbary A; Mehrzad J; Rahbar N; Dehghani H
Mol Biol Rep; 2023 Oct; 50(10):8589-8601. PubMed ID: 37644368
[TBL] [Abstract] [Full Text] [Related]
7. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic colorectal cancer on pembrolizumab: A Case Report.
Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431
[TBL] [Abstract] [Full Text] [Related]
8. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in colorectal cancer and Invasive Breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
9. Electrochemical biotool for the dual determination of epithelial mucins associated to prognosis and minimal residual disease in colorectal cancer.
Tejerina-Miranda S; Blázquez-García M; Serafín V; Montero-Calle A; Garranzo-Asensio M; Reviejo AJ; Pedrero M; Pingarrón JM; Barderas R; Campuzano S
Int J Biol Macromol; 2023 Sep; 248():125996. PubMed ID: 37499706
[TBL] [Abstract] [Full Text] [Related]
10. GART Functions as a Novel Methyltransferase in the RUVBL1/β-Catenin Signaling Pathway to Promote Tumor Stemness in colorectal cancer.
Tang C; Ke M; Yu X; Sun S; Luo X; Liu X; Zhou Y; Wang Z; Cui X; Gu C; Yang Y
Adv Sci (Weinh); 2023 Sep; 10(25):e2301264. PubMed ID: 37439412
[TBL] [Abstract] [Full Text] [Related]
11. Dissecting the genetic heterogeneity of gastric cancer.
Hess T; Maj C; Gehlen J; Borisov O; Haas SL; Gockel I; Vieth M; Piessen G; Alakus H; Vashist Y; Pereira C; Knapp M; Schüller V; Quaas A; Grabsch HI; Trautmann J; Malecka-Wojciesko E; Mokrowiecka A; Speller J; Mayr A; Schröder J; Hillmer AM; Heider D; Lordick F; Pérez-Aísa Á; Campo R; Espinel J; Geijo F; Thomson C; Bujanda L; Sopeña F; Lanas Á; Pellisé M; Pauligk C; Goetze TO; Zelck C; Reingruber J; Hassanin E; Elbe P; Alsabeah S; Lindblad M; Nilsson M; Kreuser N; Thieme R; Tavano F; Pastorino R; Arzani D; Persiani R; Jung JO; Nienhüser H; Ott K; Schumann RR; Kumpf O; Burock S; Arndt V; Jakubowska A; Ławniczak M; Moreno V; Martín V; Kogevinas M; Pollán M; Dąbrowska J; Salas A; Cussenot O; Boland-Auge A; Daian D; Deleuze JF; Salvi E; Teder-Laving M; Tomasello G; Ratti M; Senti C; De Re V; Steffan A; Hölscher AH; Messerle K; Bruns CJ; Sīviņš A; Bogdanova I; Skieceviciene J; Arstikyte J; Moehler M; Lang H; Grimminger PP; Kruschewski M; Vassos N; Schildberg C; Lingohr P; Ridwelski K; Lippert H; Fricker N; Krawitz P; Hoffmann P; Nöthen MM; Veits L; Izbicki JR; Mostowska A; Martinón-Torres F; Cusi D; Adolfsson R; Cancel-Tassin G; Höblinger A; Rodermann E; Ludwig M; Keller G; Metspalu A; Brenner H; Heller J; Neef M; Schepke M; Dumoulin FL; Hamann L; Cannizzaro R; Ghidini M; Plaßmann D; Geppert M; Malfertheiner P; Gehlen O; Skoczylas T; Majewski M; Lubiński J; Palmieri O; Boccia S; Latiano A; Aragones N; Schmidt T; Dinis-Ribeiro M; Medeiros R; Al-Batran SE; Leja M; Kupcinskas J; García-González MA; Venerito M; Schumacher J
EBioMedicine; 2023 Jun; 92():104616. PubMed ID: 37209533
[TBL] [Abstract] [Full Text] [Related]
12. A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.
Sur D; Lungulescu C; Dumitrescu EA; Afrăsânie V; Spînu Ș; Lungulescu CV; Schmoll HJ
Expert Rev Anticancer Ther; 2023 Jun; 23(6):633-641. PubMed ID: 37127555
[TBL] [Abstract] [Full Text] [Related]
13. Clinicopathological Factors Affecting Mucin 1, Mucin 2, and Mucin 5AC Staining in Patients who Underwent Resection for colorectal cancer.
Anuk T; Beseren H; Polat Y; Ozden O; Kalayci T
J Coll Physicians Surg Pak; 2023 Mar; 33(3):335-340. PubMed ID: 36945166
[TBL] [Abstract] [Full Text] [Related]
14. Immunophenotypic profiles and prognosis for colorectal mucinous adenocarcinomas are dependent on anatomic location.
Patel C; Behring M; Al Diffalha S; Dhall D; Lee G; Shanmugam C; Grizzle WE; Manne U
Cancer Med; 2023 Apr; 12(8):9637-9643. PubMed ID: 36916704
[TBL] [Abstract] [Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Trial of muc1 Peptide Vaccine for Prevention of Recurrent colorectal Adenoma.
Schoen RE; Boardman LA; Cruz-Correa M; Bansal A; Kastenberg D; Hur C; Dzubinski L; Kaufman SF; Rodriguez LM; Richmond E; Umar A; Szabo E; Salazar A; McKolanis J; Beatty P; Pai RK; Singhi AD; Jacqueline CM; Bao R; Diergaarde B; McMurray RP; Strand C; Foster NR; Zahrieh DM; Limburg PJ; Finn OJ
Clin Cancer Res; 2023 May; 29(9):1678-1688. PubMed ID: 36892581
[TBL] [Abstract] [Full Text] [Related]
16. muc1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
[TBL] [Abstract] [Full Text] [Related]
17. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
Krimmel L; Quante M; Bengsch B
Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
[TBL] [Abstract] [Full Text] [Related]
18. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract] [Full Text] [Related]
19. Genetic alterations shaping tumor response to anti-EGFR therapies.
Vaquero J; Pavy A; Gonzalez-Sanchez E; Meredith M; Arbelaiz A; Fouassier L
Drug Resist Updat; 2022 Sep; 64():100863. PubMed ID: 36063655
[TBL] [Abstract] [Full Text] [Related]
20. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract] [Full Text] [Related]
[Next]
